U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Animal Generic Drug User Fee Act (AGDUFA) Performance
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Animal Generic Drug User Fee Act (AGDUFA) Performance

 

Subscribe to FDA-TRACK Updates

 

FDA-TRACK: Animal and Veterinary
AGDUFA Performance Dashboard User Guide
FDA-TRACK Home

Animal Generic Drug Applications and Supplements

On September 30, 2023, the third reauthorization of the Animal Generic Drug User Fee Act (AGDUFA), referred to as AGDUFA IV, was signed into law. AGDUFA IV amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by reauthorizing AGDUFA for an additional five years (FY 2024 through FY 2028). AGDUFA provides FDA with resources to enhance the performance and predictability of the generic new animal drug review process resulting in more readily available safe and effective new products.

The Animal Generic Drug User Fee Performance Dashboards (AGDUFA Dashboards) provide a concise, interactive, and visual presentation of data presented in the legislatively mandated AGDUFA Performance Report to Congress for the Animal Generic Drug User Fee Act (the Report). The AGDUFA Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. The AGDUFA Dashboards reflect performance on submissions received and actions taken as of September 30, 2024. The AGDUFA Dashboards present final performance in meeting AGDUFA goals for FY 2023 and preliminary performance for FY 2024. Final AGDUFA performance data for FY 2023 will be presented in the FY 2024 AGDUFA Report and referenced in updated versions of the AGDUFA Dashboards.

FDA-Track icon: AGDUFA Generic Drug Applications and Supplements

Animal Generic Drug Applications and Supplements

The Animal Generic Drug Applications and Supplements Dashboard displays current performance relating to the review of:

  • Original Abbreviated New Animal Drug Applications (ANADAs) and Reactivations
  • Administrative ANADAs
  • Manufacturing Supplemental ANADAs and Reactivations
  • Generic Investigational New Animal Drug (JINAD) Study Submissions
  • JINAD Protocol Submissions
  • Initial JINAD Submissions

 

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top